{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:35Z","timestamp":1779322715345,"version":"3.51.4"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Expansion of myeloid blasts with suppression of normal hematopoiesis is a hallmark of acute myeloid leukemia (AML). In contrast, myeloproliferative neoplasms (MPNs) are clonal disorders characterized by overproliferation of one or more lineages that retain the ability to differentiate. Juvenile myelomonocytic leukemia (JMML) is an aggressive MPN of childhood that is clinically characterized by the overproduction of monocytic cells that can infiltrate organs, including the spleen, liver, gastrointestinal tract, and lung. Major progress in understanding the pathogenesis of JMML has been achieved by mapping out the genetic lesions that occur in patients. The spectrum of mutations described thus far in JMML occur in genes that encode proteins that signal through the Ras\/mitogen-activated protein kinase (MAPK) pathways, thus providing potential new opportunities for both diagnosis and therapy. These genes include NF1, NRAS, KRAS, PTPN11, and, most recently, CBL. While the current standard of care for patients with JMML relies on allogeneic hematopoietic stem-cell transplant, relapse is the most frequent cause of treatment failure. Rarely, spontaneous resolution of this disorder can occur but is unpredictable. This review is focused on the genetic abnormalities that occur in JMML, with particular attention to germ-line predisposition syndromes associated with the disorder. Current approaches to therapy are also discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.357","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia"],"prefix":"10.1182","volume":"2010","author":[{"given":"Mignon L.","family":"Loh","sequence":"first","affiliation":[{"name":"Department of Pediatrics and the Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111716220377100_B1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2007.06958.x","article-title":"Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options","volume":"140","author":"Niemeyer","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111716220377100_B2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V77.5.925.925","article-title":"Seletive hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors","volume":"77","author":"Emanuel","year":"1991","journal-title":"Blood"},{"key":"2019111716220377100_B3","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"2019111716220377100_B4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-3476(78)80362-X","article-title":"Neurofibromatosis and childhood leukemia","volume":"92","author":"Bader","year":"1978","journal-title":"J Pediatr"},{"key":"2019111716220377100_B5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(90)90149-9","article-title":"The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae","volume":"63","author":"Xu","year":"1990","journal-title":"Cell"},{"key":"2019111716220377100_B6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM199403033300903","article-title":"Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders","volume":"330","author":"Shannon","year":"1994","journal-title":"N Engl J Med"},{"key":"2019111716220377100_B7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ng0296-137","article-title":"Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia","volume":"12","author":"Largaespada","year":"1996","journal-title":"Nat Genet"},{"key":"2019111716220377100_B8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"key":"2019111716220377100_B9","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood.V84.10.3435.3435","article-title":"Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras","volume":"84","author":"Kalra","year":"1994","journal-title":"Blood"},{"key":"2019111716220377100_B10","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.V83.8.2248.2248","article-title":"Mutations of the N-ras gene in juvenile chronic myelogenous leukemia","volume":"83","author":"Miyauchi","year":"1994","journal-title":"Blood"},{"key":"2019111716220377100_B11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajmg.a.33183","article-title":"Proceedings from the 2009 genetic syndromes of the Ras\/MAPK pathway: From bedside to bench and back","volume":"152A","author":"Rauen","year":"2010","journal-title":"Am J Med Genet A"},{"key":"2019111716220377100_B12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"2019111716220377100_B13","article-title":"Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis","author":"Loh","year":"2003","journal-title":"Blood"},{"key":"2019111716220377100_B14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"2019111716220377100_B15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"2019111716220377100_B16","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"key":"2019111716220377100_B17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2004-11-4207","article-title":"Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells","volume":"106","author":"Schubbert","year":"2005","journal-title":"Blood"},{"key":"2019111716220377100_B18","article-title":"Human somatic PTPN11 mutations induce hematopoietic cell hypersensitivity to granulocyte-macrophage colony stimulating factor","author":"Chan","year":"2005","journal-title":"Blood"},{"key":"2019111716220377100_B19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm1084","article-title":"Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation","volume":"10","author":"Araki","year":"2004","journal-title":"Nat Med"},{"key":"2019111716220377100_B20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","article-title":"Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations","volume":"7","author":"Mohi","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111716220377100_B21","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1038\/sj.onc.1210361","article-title":"Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11","volume":"26","author":"Flotho","year":"2007","journal-title":"Oncogene"},{"key":"2019111716220377100_B22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood-2005-11-011486","article-title":"Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies","volume":"108","author":"Stephens","year":"2006","journal-title":"Blood"},{"key":"2019111716220377100_B23","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"key":"2019111716220377100_B24","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"2019111716220377100_B25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"2019111716220377100_B26","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","article-title":"Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia","volume":"115","author":"Muramatsu","year":"2010","journal-title":"Blood"},{"key":"2019111716220377100_B27","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","article-title":"Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies","volume":"27","author":"Makishima","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111716220377100_B28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrm1762","article-title":"The Cbl interactome and its functions","volume":"6","author":"Schmidt","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019111716220377100_B29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"2019111716220377100_B30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111716220377100_B31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pbc.20176","article-title":"Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia","volume":"44","author":"Gratias","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2019111716220377100_B32","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","article-title":"Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations","volume":"109","author":"Matsuda","year":"2007","journal-title":"Blood"},{"key":"2019111716220377100_B33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2007-09-111831","article-title":"Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations","volume":"111","author":"Flotho","year":"2008","journal-title":"Blood"},{"key":"2019111716220377100_B34","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"key":"2019111716220377100_B35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1046\/j.1365-2141.2003.04361.x","article-title":"Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival","volume":"121","author":"Passmore","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111716220377100_B36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"key":"2019111716220377100_B37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1203\/PDR.0b013e3181961d2a","article-title":"Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia","volume":"65","author":"Yoshida","year":"2009","journal-title":"Pediatr Res"},{"key":"2019111716220377100_B38","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2009.24.4426","article-title":"Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia","volume":"28","author":"Bresolin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716220377100_B39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.21038","article-title":"Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria","volume":"49","author":"Bergstraesser","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2019111716220377100_B40","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood.V106.11.2587.2587","article-title":"Phase ii window study of the farnesyltransferase inhibitor R115777 (Zarnestra\u00ae) in untreated juvenile myelomonocytic leukemia (JMML): A Children's Oncology Group Study [Abstract]","volume":"106","author":"Castleberry","year":"2005","journal-title":"Blood"},{"key":"2019111716220377100_B41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2008.08.022","article-title":"Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium","volume":"33","author":"Chan","year":"2009","journal-title":"Leuk Res"},{"key":"2019111716220377100_B42","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2007-06-093302","article-title":"Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia","volume":"111","author":"Archambeault","year":"2008","journal-title":"Blood"},{"key":"2019111716220377100_B43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"14","author":"Kotecha","year":"2008","journal-title":"Cancer Cell"},{"key":"2019111716220377100_B44","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/138945007780830773","article-title":"Targeting RAS signaling pathways in juvenile myelomonocytic leukemia","volume":"8","author":"Flotho","year":"2007","journal-title":"Curr Drug Targets"},{"key":"2019111716220377100_B45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.leu.2402407","article-title":"Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group","volume":"16","author":"Manabe","year":"2002","journal-title":"Leukemia"},{"key":"2019111716220377100_B46","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2141.2005.05489.x","article-title":"Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia","volume":"129","author":"Yoshimi","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111716220377100_B47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2403721","article-title":"Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia","volume":"19","author":"Yoshimi","year":"2005","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/357\/1493570\/bep00110000357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/357\/1493570\/bep00110000357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:30:01Z","timestamp":1712122201000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/357\/96381\/Childhood-Myelodysplastic-Syndrome-Focus-on-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.357","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}